Drug Search Results
More Filters [+]

Androstanolone

Alternative Names: androstanolone, dihydrotestosterone
Latest Update: 2024-11-13
Latest Update Note: News Article

Product Description

A hormone made from testosterone in the prostate, testes, and certain other tissues. It is needed to develop and maintain male sex characteristics, such as facial hair, deep voice, and muscle growth. High amounts of androstanolone may increase the growth of prostate cancer and make it harder to treat. Also called DHT and dihydrotestosterone. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/androstanolone)

Mechanisms of Action: AR Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Transdermal,Topical

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: France | India | Slovenia | Taiwan | United Kingdom

Approved Indications: None

Known Adverse Events: None

Company: Ascend
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Androstanolone

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Bone Cancer|Prostate Cancer|Protein Deficiency|Bladder Cancer|Inflammation|Hypogonadism|Testicular Cancer|Pituitary Cancer|Pregnancy Outcomes|Hypopituitarism|Prostatic Diseases|Skin Diseases, Vascular|Vascular Cancer|Prostatic Hyperplasia|Hypothalamic Diseases|Hypothalamic Cancer|Testicular Diseases|Deficiency Diseases|Anal Gland Cancer|Skin Cancer|Breast Cancer|Pituitary Diseases

Phase 1: Prostate Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

FDHT - version 1, 9 March 2015

P2

Terminated

Prostate Cancer

2018-09-15

[18F]FDHT PET in hormone naive prostate cancer

P2

Active, not recruiting

Bone Cancer|Prostate Cancer

2016-02-11

2012-003981-42

P2

Completed

Breast Cancer

2015-05-13

IRB00015971

P1

Terminated

Prostate Cancer

2013-03-01

Recent News Events